Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 587

1.

The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.

Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI.

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20.

PMID:
17555784
2.

Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice.

Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H.

J Exp Ther Oncol. 2009;8(1):43-51.

PMID:
19827270
3.

Licochalcone A inhibits the growth of colon carcinoma and attenuates cisplatin-induced toxicity without a loss of chemotherapeutic efficacy in mice.

Lee CK, Son SH, Park KK, Park JH, Lim SS, Kim SH, Chung WY.

Basic Clin Pharmacol Toxicol. 2008 Jul;103(1):48-54. doi: 10.1111/j.1742-7843.2008.00238.x. Epub 2008 Jul 1.

4.

Extract of Prunus persica flesh (PPFE) improves chemotherapeutic efficacy and protects against nephrotoxicity in cisplatin-treated mice.

Lee CK, Park KK, Hwang JK, Lee SK, Chung WY.

Phytother Res. 2009 Jul;23(7):999-1005. doi: 10.1002/ptr.2740.

PMID:
19140122
5.
6.

Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.

Dominguez MF, Macias RI, Izco-Basurko I, de La Fuente A, Pascual MJ, Criado JM, Monte MJ, Yajeya J, Marin JJ.

J Pharmacol Exp Ther. 2001 Jun;297(3):1106-12.

PMID:
11356935
7.

Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.

Zhang JS, Imai T, Otagiri M.

Arch Toxicol. 2000 Aug;74(6):300-7.

PMID:
11005675
8.

Low-dose supplementation with active hexose correlated compound improves the immune response to acute influenza infection in C57BL/6 mice.

Nogusa S, Gerbino J, Ritz BW.

Nutr Res. 2009 Feb;29(2):139-43. doi: 10.1016/j.nutres.2009.01.005.

PMID:
19285605
9.

Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses.

Gao Y, Zhang D, Sun B, Fujii H, Kosuna K, Yin Z.

Cancer Immunol Immunother. 2006 Oct;55(10):1258-66. Epub 2005 Dec 16.

PMID:
16362410
10.

Magnesium depletion enhances cisplatin-induced nephrotoxicity.

Lajer H, Kristensen M, Hansen HH, Nielsen S, Fr√łkiaer J, Ostergaard LF, Christensen S, Daugaard G, Jonassen TE.

Cancer Chemother Pharmacol. 2005 Nov;56(5):535-42. Epub 2005 Jun 10.

PMID:
15947931
11.

Maitake beta-glucan enhances therapeutic effect and reduces myelosupression and nephrotoxicity of cisplatin in mice.

Masuda Y, Inoue M, Miyata A, Mizuno S, Nanba H.

Int Immunopharmacol. 2009 May;9(5):620-6. doi: 10.1016/j.intimp.2009.02.005. Epub 2009 Feb 26.

PMID:
19249389
12.

Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen.

Baldew GS, McVie JG, van der Valk MA, Los G, de Goeij JJ, Vermeulen NP.

Cancer Res. 1990 Nov 1;50(21):7031-6.

13.

Mobilization of bone marrow cells by G-CSF rescues mice from cisplatin-induced renal failure, and M-CSF enhances the effects of G-CSF.

Iwasaki M, Adachi Y, Minamino K, Suzuki Y, Zhang Y, Okigaki M, Nakano K, Koike Y, Wang J, Mukaide H, Taketani S, Mori Y, Takahashi H, Iwasaka T, Ikehara S.

J Am Soc Nephrol. 2005 Mar;16(3):658-66. Epub 2005 Feb 2.

14.

Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice.

Nakashima-Kamimura N, Mori T, Ohsawa I, Asoh S, Ohta S.

Cancer Chemother Pharmacol. 2009 Sep;64(4):753-61. doi: 10.1007/s00280-008-0924-2. Epub 2009 Jan 16.

PMID:
19148645
15.

Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.

Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.

Chem Biol Interact. 2004 Jun 30;148(1-2):37-48.

PMID:
15223355
16.

Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm.

Arafa HM, Abdel-Hamid MA, El-Khouly AA, Elmazar MM, Osman AM.

Toxicology. 2006 May 1;222(1-2):103-13. Epub 2006 Mar 6.

PMID:
16567030
17.
18.

The protective effect of melatonin on cisplatin nephrotoxicity.

Sener G, Satiroglu H, Kabasakal L, Arbak S, Oner S, Ercan F, Keyer-Uysa M.

Fundam Clin Pharmacol. 2000 Nov-Dec;14(6):553-60.

PMID:
11206705
19.

Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.

Konstantinov S, Topashka-Ancheva M, Karaivanova M, Zoneva G, Galova I.

Neoplasma. 1994;41(5):253-8.

PMID:
7854494
20.

Supplemental Content

Support Center